Syndax Pharmaceuticals Inc- 详细介绍、公司背景、业务范围、财务数据以及市场表现

关于 Syndax Pharmaceuticals Inc 公司

Syndax Pharmaceuticals, Inc. 是一家临床阶段的生物制药公司。该公司专注于开发癌症疗法。其候选产品包括 revumenib 和 axatilimab。该公司正在开发 revumenib，这是一种强效、选择性、小分子抑制剂，可抑制 menin-MLL 结合相互作用，用于治疗 KMT2A 重排（也称为混合谱系白血病重排）、急性白血病（包括急性淋巴细胞白血病和急性髓细胞白血病 (AML)）和核磷蛋白 1（也称为 NPM1，突变体 A）。该公司还在探索使用 revumenib 治疗实体瘤，特别是其在转移性结直肠癌中的活性。该公司还在开发 axatilimab，这是一种单克隆抗体，可阻断慢性移植物抗宿主病 (cGVHD) 以及特发性肺纤维化中的集落刺激因子 1 受体 (CSF-1R)。 Entinostat 是一种口服小分子候选产品，对癌细胞和免疫调节细胞有直接作用。

Syndax Pharmaceuticals Inc简介



公司代码SNDX

公司名称Syndax Pharmaceuticals Inc

上市日期Mar 03, 2016

CEOMr. Michael A. Metzger

员工数量270

证券类型Ordinary Share

年结日Mar 03

公司地址730 Third Avenue

城市NEW YORK

上市交易所NASDAQ Global Select Consolidated

国家United States of America

邮编10017

电话17814191400

网址https://syndax.com/

公司代码SNDX

上市日期Mar 03, 2016

CEOMr. Michael A. Metzger

Syndax Pharmaceuticals Inc公司高管



名称

名称/职务

职务

持股

持股变动

Mr. Michael A. Metzger

Chief Executive Officer, Director

298.66K

--

Mr. Dennis G. Podlesak

Independent Chairman of the Board

127.33K

--

Mr. Keith A. Katkin, CPA

Independent Director

75.00K

+15.38%

Mr. Steven (Steve) Closter

Chief Commercial Officer

70.90K

--

Mr. Pierre Legault, CPA

Independent Director

65.00K

-10.96%

Mr. Nicholas A.J. Botwood

Head - Research and Development, Chief Medical Officer

--

Ms. Jennifer A. Jarrett

Independent Director

--

Dr. Aleksandra Rizo, M.D., Ph.D.

Independent Director

--

Mr. Keith A. Goldan, CPA

Chief Financial Officer

--

Dr. Martin H. Huber, M.D.

Independent Director

--

名称

名称/职务

职务

持股

持股变动

Mr. Michael A. Metzger

Chief Executive Officer, Director

298.66K

--

Mr. Dennis G. Podlesak

Independent Chairman of the Board

127.33K

--

Mr. Keith A. Katkin, CPA

Independent Director

75.00K

+15.38%

Mr. Steven (Steve) Closter

Chief Commercial Officer

70.90K

--

Mr. Pierre Legault, CPA

Independent Director

65.00K

-10.96%

Mr. Nicholas A.J. Botwood

Head - Research and Development, Chief Medical Officer

--

收入明细

暂无数据

暂无数据

业务

地区

暂无数据

股东统计

更新时间: 8月16日周六

持股股东

股东类型

持股股东

占比

Kynam Capital Management LP

9.80%

BlackRock Institutional Trust Company, N.A.

8.70%

Goldman Sachs & Company, Inc.

5.98%

The Vanguard Group, Inc.

5.89%

Eversept Partners, LP

4.68%

其他

64.96%

持股股东

占比

Kynam Capital Management LP

9.80%

BlackRock Institutional Trust Company, N.A.

8.70%

Goldman Sachs & Company, Inc.

5.98%

The Vanguard Group, Inc.

5.89%

Eversept Partners, LP

4.68%

其他

64.96%

股东类型

持股股东

占比

Hedge Fund

48.37%

Investment Advisor

34.79%

Investment Advisor/Hedge Fund

21.09%

Research Firm

11.71%

Venture Capital

4.19%

Individual Investor

1.30%

Pension Fund

0.77%

Bank and Trust

0.47%

Insurance Company

0.03%

机构持股



更新时间: 10月1日周三

报告期

机构数

持股数

持股占比

持股变动

2025Q3

456

105.70M

121.61%

-16.72M

2025Q2

453

106.14M

123.25%

-9.50M

2025Q1

465

105.51M

122.65%

-11.55M

2024Q4

466

101.18M

117.63%

-2.44M

2024Q3

454

91.99M

107.96%

-12.90M

2024Q2

424

90.42M

106.49%

-16.61M

2024Q1

417

93.25M

109.83%

-11.76M

2023Q4

407

91.08M

107.54%

+9.06M

2023Q3

394

77.71M

113.61%

-12.98M

2023Q2

385

77.69M

113.93%

-12.13M

股东持股明细



名称

持股数

占比

持股变动

变动比例

公告日期

Kynam Capital Management LP

8.52M

9.89%

--

Jun 30, 2025

BlackRock Institutional Trust Company, N.A.

7.56M

8.77%

+745.47K

+10.94%

Jun 30, 2025

Goldman Sachs & Company, Inc.

5.20M

6.03%

+1.74M

+50.14%

Jun 30, 2025

The Vanguard Group, Inc.

5.01M

5.82%

+158.25K

+3.26%

Jun 30, 2025

Eversept Partners, LP

4.07M

4.72%

-146.91K

-3.49%

Jun 30, 2025

BofA Global Research (US)

3.84M

4.46%

+967.87K

+33.71%

Jun 30, 2025

State Street Investment Management (US)

3.44M

4%

-528.98K

-13.32%

Jun 30, 2025

StemPoint Capital LP

2.37M

2.75%

+774.04K

+48.42%

Jun 30, 2025

Franklin Advisers, Inc.

2.33M

2.71%

+296.77K

+14.57%

Jun 30, 2025

Point72 Asset Management, L.P.

2.13M

2.47%

-1.88M

-46.93%

Jun 30, 2025

持股ETF



更新时间: 11月6日周四

机构名称

占比

Tema Oncology ETF

2.12%

Virtus LifeSci Biotech Clinical Trials ETF

1.04%

SPDR S&P Biotech ETF

0.56%

Simplify Health Care ETF

0.35%

Inspire Small/Mid Cap ESG ETF

0.32%

Direxion Daily S&P Biotech Bull 3X Shares

0.29%

ProShares Ultra Nasdaq Biotechnology

0.14%

Invesco Nasdaq Biotechnology ETF

0.13%

iShares Biotechnology ETF

0.12%

iShares Russell 2000 Growth ETF

0.07%

Tema Oncology ETF

占比2.12%

Virtus LifeSci Biotech Clinical Trials ETF

占比1.04%

SPDR S&P Biotech ETF

占比0.56%

Simplify Health Care ETF

占比0.35%

Inspire Small/Mid Cap ESG ETF

占比0.32%

Direxion Daily S&P Biotech Bull 3X Shares

占比0.29%

ProShares Ultra Nasdaq Biotechnology

占比0.14%

Invesco Nasdaq Biotechnology ETF

占比0.13%

iShares Biotechnology ETF

占比0.12%

iShares Russell 2000 Growth ETF

占比0.07%

分红派息



近5年累计派现 0.00 美元

公告日期

分红计划

股权登记日

现金发放日

除权除息日

暂无数据

拆合股



公告日期

类型

比率

暂无数据

公告日期

类型

比率

暂无数据